Second generation antipsychotics are currently the drugs of choice for the treatment of schiz­ophrenia and bipolar mania, as well as for behavioural symptoms in patients with dementia. All these diseases represent an important healthcare problem in Europe, so that early treat­ment is recommended. Due to improved patient compliance, new pharmaceutical forms of already proven therapy are developed. Orally disintegrated tablets disintegrate rapidly in the mouth without water. Therefore, a study was conducted with risperidone (Torendo® Q-Tab®, Krka, d. d., Novo Mesto) in 487 patients with schizophrenia, bipolar mania and behavioural disturbances in dementia patients. Risperidone in recommended doses significantly improved symptoms in 77% of patients. Its tolerability was very good, as adverse reactions related to the medicine occurred in 11.9% of the patients. 90% of the patients were satisfied with treat­ment with Torendo® Q-Tab®, and this proved very good acceptability of our risperidone in the orodispersible formulation. The most frequent reason why patients choose Torendo Q-Tab were: easy swallowing of the medicine, easy administration/intake of the medicine, ability to take it at anyplace and anytime, greater comfort that taking the medicine is less conspic­uous, improved ability to perform everyday activities.